HLOC
REGN icon

H.L. Ormond & Company’s Regeneron Pharmaceuticals REGN Stock Holding History

H.L. Ormond & Company’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$230K Sell
334
-29
-8% -$18.3K 0.37% 83
2022
Q2 		$215K Sell
363
-156
-30% -$101K 0.35% 88
2022
Q1 		$362K Sell
519
-4
-0.8% -$2.53K 0.44% 79
2021
Q4 		$323K Buy
+523
New +$322K 0.38% 85

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

H.L. Ormond & Company's REGN Position: Q3 2022 in Review

H.L. Ormond & Company reduced its Regeneron Pharmaceuticals (REGN) stake by 8% in Q3 2022, selling an estimated $18.3K and leaving 334 shares worth $230K. The position accounts for 0.37% of the portfolio, ranked #83.

H.L. Ormond & Company first reported a position in REGN in Q4 2021 and has held it in 4 quarters since. The position peaked at $362K in Q1 2022. 1,080 funds tracked by Wall St. Rank hold REGN as of Q3 2022.

  • H.L. Ormond & Company held 334 shares of Regeneron Pharmaceuticals worth $230K as of Q3 2022.
  • H.L. Ormond & Company sold 29 Regeneron Pharmaceuticals shares in Q3 2022, an estimated $18.3K.
  • Regeneron Pharmaceuticals made up 0.37% of H.L. Ormond & Company's portfolio in Q3 2022, its #83 holding.
  • H.L. Ormond & Company first reported a position in Regeneron Pharmaceuticals in Q4 2021 and has held it in 4 quarters since.
  • H.L. Ormond & Company's Regeneron Pharmaceuticals position peaked at $362K in Q1 2022.
  • 1,080 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2022.

Based on H.L. Ormond & Company's 13F filing for Q3 2022, filed 14 Nov 2022.